Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Glucocorticoids comprise an important class of hormonal mediators of fuel and protein homeostasis in normal and pathological scenarios. In skeletal muscle, exposure to glucocorticoids is characterized by a reduction in protein synthetic rate coincident with hampered translation initiation. However, it is unclear whether this involves attenuation of anabolic stimuli or is simply due to inhibition of the basally activated translational apparatus. Therefore, this inquiry was designed to determine whether leucine, administered orally, could rescue the translational inhibition induced by glucocorticoids. Dexamethasone, injected intraperitoneally, acutely diminished protein synthetic rates to 80% of control values in skeletal muscle from rat hindlimb. The eukaryotic initiation factor (eIF)4 regulatory element was simultaneously and negatively impacted via sequestration of eIF4E by the hypophosphorylated form of the translational suppressor, eIF4E binding protein 1 (4E-BP1). The 70-kDa ribosomal protein S6 kinase (S6K1) was also dephosphorylated, notably at T389, in response to glucocorticoids. Leucine, administered orally, effectively restored each aforementioned translational parameter to control levels. Inasmuch as leucine's potency in modulation of the translational machinery, and indeed of protein turnover in general, is widely appreciated, this amino acid may prove useful in normalizing the impairment of mRNA translation associated with various muscle-wasting pathologies, such as glucocorticoid excess.
translation initiation; ribosomal protein S6 kinase; eukaryotic initiation factor 4E; 4E binding protein 1
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
GLOBAL SKELETAL MUSCLE CATABOLISM and negative nitrogen balance are symptoms secondary to a variety of pathological scenarios involving glucocorticoid dysfunction. When in excess, glucocorticoid hormones impact the protein synthetic (20-22) and degradative (10, 23, 27) machinery in skeletal muscle and, in doing so, render the tissue catabolic. It has been clear for several decades that glucocorticoids operate largely through activation of a ligand-inducible nuclear receptor that doubles as a multifunctional transcription factor. As such, glucocorticoids induce or repress target gene products. Although glucocorticoids have been shown to inhibit ribosomal protein S6 kinase (S6K1) activation in T cells (18) and reduce the phosphorylation status of S6K1 and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) in L6 myoblasts (26), the identity of intermediating gene targets is entirely cryptic. Presumably, however, glucocorticoids modulate the phosphorylation status of S6K1 and 4E-BP1 by transcriptional activation and/or repression of genes, the products of which are capable of influencing the phosphorylation of these translational effectors.
The eIF4 family of eukaryotic initiation factors is recognized as a critical regulatory element governing the initiation of mRNA translation (reviewed in Ref. 16). The speed at which ribosomes engage mRNA for subsequent peptide synthesis is governed by the efficiency of the translation initiation cycle, which, under some circumstances, is determined by the availability of the mRNA cap recognition factor, eIF4E. A family of translational repressors, the 4E-BPs, are phosphoproteins that, when hypophosphorylated, competitively exclude eIF4E from the remainder of the translational apparatus. However, the inhibition of eIF4E imposed by the 4E-BPs is relinquished on 4E-BP phosphorylation, which liberates eIF4E and facilitates assembly of the heterotrimeric (eIF4E, eIF4G, and eIF4A) initiation complex known as eIF4F. Glucocorticoids markedly suppress protein synthetic rate in skeletal muscle concomitant with dephosphorylation of 4E-BP1, which is the predominant 4E-BP isoform in this tissue, as well as disassembly of eIF4F (24). S6K1 is similarly impacted, in that exposure to glucocorticoids induces a robust dephosphorylation and, thereby, inactivation of the kinase (18). S6K1 phosphorylates ribosomal proteins such as S6 (13) and S17 (19); importantly, S6K1-mediated phosphorylation of S6 at five carboxy-terminal serine residues may serve to select those mRNAs encoding elements of the translational machinery and thereby influence the overall protein synthetic capacity of the cell (11, 12).
Amino acid sufficiency is demonstrably requisite for efficient
propagation of modulatory signals to the translational apparatus. Although various physiological roles have been ascribed to individual amino acids, the branched-chain group, and particularly leucine, has
been implicated in the regulation of protein metabolism (2, 17,
29). Indeed, leucine, through as yet undiscovered mechanisms, activates an intracellular signal transduction pathway that requires the protein kinase activity associated with, or intrinsic to, the
mammalian target of rapamycin (mTOR) (9). mTOR is a
component of an ancient nutrient-sensing pathway that, in mammalian
cells, regulates activation of S6K1 and eIF4E availability [the latter through phosphorylation of 4E-BPs (reviewed in Refs. 3 and 28)]. Hence, the mTOR signaling module has emerged as a central element in the regulation of translational homeostasis (Fig.
1).
|
Leucine, administered as an oral bolus, completely reverses the reduction in protein synthetic rate induced by fasting, an effect that appears to be mediated by eIF4F and not eIF2B (1). Along similar lines, glucocorticoids negatively affect protein synthetic rates in skeletal muscle primarily through inhibition of eIF4F and independently of eIF2B (24). Thus potential counterregulatory control of translation initiation by leucine and glucocorticoids is predicted to occur largely via their respective influences on the assembly of eIF4F. Therefore, we sought to determine whether the adverse effects of glucocorticoids on the eIF4 system could be corrected by oral leucine supplementation and, moreover, whether a parallel restoration of protein synthesis was attainable.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials. Mouse monoclonal anti-eIF4E antibody was raised against recombinant human eIF4E by the method described earlier (14). Rabbit polyclonal anti-eIF4G antibody was raised against the corresponding human protein, which was expressed in and purified from Sf9 insect cells using the baculovirus expression system, as detailed elsewhere (5, 14). Rabbit polyclonal anti-S6K1, anti-phospho-T389-S6K1, and anti-4E-BP1 antibodies were purchased from Santa Cruz Biotechnology. Polyvinylidene difluoride membranes were purchased from Bio-Rad. Enhanced chemiluminescence detection reagents and horseradish peroxide-conjugated sheep anti-mouse and donkey anti-rabbit Igs were purchased from Amersham Life Sciences.
Animals. The animal facilities and protocol were reviewed and approved by the Animal Care and Use Committee of The Pennsylvania State University College of Medicine. Male Sprague-Dawley rats weighing 200-300 g were maintained on a 12:12 h light-dark cycle and allowed free access to food (Harlan-Teklad Rodent Chow, Madison, WI) and water.
Rats were given dexamethasone sodium phosphate (American Reagent Laboratories, Shirley, NY; 100 µg/100 g body wt ip) or an equal volume of vehicle (0.15 M NaCl). Three hours after drug administration, one-half of the control and one-half of the dexamethasone-treated group received an intragastric bolus of 2.5 ml/100 g body wt L-leucine (54.0 g/l) in distilled water.Administration of metabolic tracer.
A metabolic tracer consisting of a flooding dose (1 ml/100 g body wt)
of L-[2,3,4,5,6-3H]phenylalanine (150 mM
containing 100 µCi/ml) was injected via the tail vein 50 min after
leucine administration for the measurement of synthesis of total mixed
proteins in skeletal muscle, as described previously (6).
Exactly 1 h after leucine administration, animals were killed by
decapitation. Trunk blood was collected and centrifuged at 1,800 g for 10 min to obtain serum. The right gastrocnemius and
plantaris were excised as a unit 10 min after administration of the
radiolabel for the measurement of skeletal muscle protein synthesis and
then quickly frozen in liquid nitrogen. The contralateral muscles were
similarly excised, weighed, and homogenized in seven volumes of
buffer A (20 mM HEPES, pH 7.4, 100 mM KCl, 0.2 mM EDTA, 2 mM
EGTA, 1 mM dithiothreitol, 50 mM NaF, 50 mM -glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, and 0.5 mM sodium
vanadate). The homogenate was immediately centrifuged at 10,000 g for 10 min at 4°C. The supernatant was reserved for Western analysis as described below. All serum and tissue samples were
stored at
80°C.
Determination of rates of protein synthesis. Fractional rates of protein synthesis were estimated on the basis of the incorporation of [3H]phenylalanine into muscle proteins, with the specific radioactivity of serum phenylalanine as representative of the precursor pool (15). The elapsed time from injection of the metabolic tracer until freezing of muscle in liquid nitrogen was recorded as the actual time for incorporation of the radiolabeled amino acid into protein.
Quantitation of eIF4E, 4E-BP1 · eIF4E, and eIF4G · eIF4E complexes. Quantitation of the respective factors and complexes was carried out exactly as outlined previously (31).
Quantitation of phosphorylated and unphosphorylated 4E-BP1 in
skeletal muscle homogenates.
Quantitation of the phosphorylation state of 4E-BP1 was carried out
exactly as described elsewhere (31). The data were
expressed as the percentage of total 4E-BP1 in the -form.
Quantitation of phosphorylation state of S6K1.
Whole muscle homogenates were centrifuged at 10,000 g for 10 min at 4°C. The supernatants were collected and subjected to SDS-PAGE
and Western blotting essentially as outlined above using a rabbit
polyclonal anti-S6K1 antibody. In a manner analagous to 4E-BP1, S6K1
resolves into multiple electrophoretic forms after SDS-PAGE, wherein
increasing phosphorylation retards mobility (8).
Therefore, more slowly migrating species generally reflect a greater
degree of phosphorylation and thus activation. The data were expressed
as the percentage of the total S6K1 pool in the hyperphosphorylated,
i.e., non-, forms. Therefore, the data are representative of S6K1 phosphorylation.
Statistical analysis. All data were analyzed using one-way ANOVA and Tukey's posttest comparisons. Statistical significance was defined as P < 0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Glucocorticoids and the branched-chain amino acid leucine, despite
their opposing influences on the protein synthetic apparatus, are
similar with regard to selection of regulatory targets, namely, eIF4F.
In vivo, neither acute glucocorticoid exposure (24) nor leucine administration (1) affects other known mechanisms
involved in regulation of translation initiation such as the
phosphorylation state of the -subunit of eIF2 or the catalytic
activity of eIF2B. Four hours subsequent to intraperitoneal injection
of dexamethasone, protein synthetic rates were reduced to 80% of that
recorded in control, saline-injected rats (Table
1); this effect was entirely reversed
after administration of leucine. As reported previously (25), serum insulin concentrations were not significantly
altered by any treatment, although administration of leucine slightly reduced circulating concentrations of glucose in dexamethasone-treated animals (Table 1).
|
To address the mechanistic nature of opposing translational control by
dexamethasone and leucine, known regulatory processes involved in mRNA
translation were examined. eIF4E recognizes the N7-methylguanosine cap at the 5' terminus of
most eukaryotic transcripts and thereby targets these mRNAs to the
ribosome. However, the facility of eIF4E in this process is modulated
by phosphorylation of 4E-BPs, which, when hypophosphorylated, sequester
eIF4E from the translational machinery, whereas the hyperphosphorylated
4E-BPs lack significant affinity for eIF4E. Whereas dexamethasone
diminished the proportion of 4E-BP1 in the highly phosphorylated
-form, i.e., the disinhibited form, to ~60% of control values,
leucine corrected 4E-BP1 dephosphorylation by glucocorticoids, as
evidenced by restoration of the percentage of 4E-BP1-
to near that
of the control animal (Fig. 2).
|
Both 4E-BPs and eIF4G display homology within an eIF4E recognition
sequence that renders the association of these factors with eIF4E
mutually exclusive. Immunoprecipitation of eIF4E reveals that, although
glucocorticoids increase by 50% its association with 4E-BP1, the
sequestration of eIF4E by 4E-BP1 is markedly attenuated after
administration of leucine (Fig. 3).
Since, when liberated, eIF4E favors interaction with eIF4G, it was not
surprising that destabilization of the glucocorticoid-induced
eIF4E · 4E-BP1 complex by leucine was accompanied by the
association of eIF4E with eIF4G (Fig. 4).
|
|
4E-BP1 and S6K1 are commonly inhibited by rapamycin and are
coordinately regulated under many circumstances. Because S6K1 affects
the translation of mRNAs encoding components of the protein synthetic
apparatus, such as ribosomal proteins and elongation factors, the
phosphorylation state of S6K1 under these conditions was evaluated. In
dexamethasone-treated animals, total S6K1 exhibited a bias toward
faster mobility as visualized by SDS-PAGE and immunoblotting (Fig.
5A). Since the rate of
migration of the kinase is inversely proportional to its degree of
phosphorylation (8), these results suggest that
glucocorticoids induce dephosphorylation of the enzyme. Indeed, the
proportion of S6K1 existing in hyperphosphorylated species (relative to
S6K1-) diminished appreciably in response to glucocorticoids (Fig.
5), whereas leucine exerted an opposing effect. Moreover, the
glucocorticoid-induced disappearance of slower electrophoretic species
was associated with dephosphorylation of S6K1 at T389 (Fig.
5A), a site at which phosphorylation heralds full enzyme
activation (3, 30). Administration of leucine after
dexamethasone completely reversed the glucocorticoid-induced dephosphorylation of the kinase and returned phospho-T389
immunoreactivity to control levels (Fig. 5).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although the drastic adverse effects of glucocorticoids on protein metabolism, particularly in skeletal muscle, have long been recognized, relatively little information is available regarding the intracellular events involved in this process. The action of glucocorticoids, and indeed many other steroid hormones, is mediated primarily via specific, ligand-activated intracellular receptors. The recognition of glucocorticoid by its receptor (GR) induces a conformational change in the receptor that exposes a nuclear localization signal; the GR is thereby targeted to the nuclear compartment. Once nuclear, the GR functions as a transcriptional activator or repressor, modulating the expression of responsive genes.
Glucocorticoids appear to influence S6K1 and 4E-BP1 function via transcriptional means, i.e., via activation or repression of target genes, since a temporal lag of 2-3 h is required for these effects to evolve (18, 26). These translational pathways appear to be inhibited downstream of phosphatidylinositol 3-kinase, since the activity of this lipid kinase is not reduced in cells treated with dexamethasone (18). Furthermore, activation of protein kinase B (PKB)/Akt as evidenced by phosphorylation of two critical sites, T308 and S473, is not hindered by glucocorticoids (25). In light of recent evidence that PKB/Akt is an authentic upstream effector of 4E-BP1 (7), but not S6K1 (4), these data imply that glucocorticoids act either downstream of or parallel to PKB/Akt in the downregulation of eIF4F and S6K1.
Several scenarios could be envisioned to account for the ability of glucocorticoids to inhibit leucine-induced activation of eIF4F and S6K1. It is likely that glucocorticoids are exerting this regulation by modulating the expression of one or more genes encoding some type of negative regulator(s). Induction of protein phosphatases that directly dephosphorylate 4E-BP1 and/or S6K1 or dephosphorylate other upstream effectors, leading to inactivation of those effectors, could account for the dephosphorylation of 4E-BP1 and S6K1. Conversely, repression of a critical upstream regulator, such as an activating kinase, could also explain this effect. Alternatively, alterations in some protein-protein interaction, which impedes activation of eIF4F and S6K1, or omission of essential upstream effectors (or 4E-BP1 and S6K1 themselves for that matter) from productive signaling networks by subcellular relocalization could hinder the activities of these translational effectors. The obvious complexity in such translational regulation will undoubtedly prove challenging to resolve.
For all biochemical parameters examined, leucine reversed the effects of glucocorticoids on S6K1 and eIF4F and, in doing so, restored protein synthetic rates to control values. The glucocorticoid-mediated impairment of the translational apparatus is associated with insufficient eIF4F assembly and inactivation of S6K1, despite unperturbed catalytic activity of eIF2B (24). It therefore appears that eIF4F function represents a critical target for translational regulation by glucocorticoids. By comparison, eIF4F assembly in skeletal muscle is attenuated with fasting, again concomitant with undiminished eIF2B activity, suggesting that the eIF4 system is rate controlling under those conditions as well. Interestingly, the fasting-induced reduction in protein synthetic rate and associated diminution of eIF4F function are readily corrected after a single bolus ingestion of leucine (1). The results presented here demonstrate that eIF4F and S6K1 are translational elements subject to counterregulation by glucocorticoids and leucine. Moreover, these data imply that a primary defect in the function of eIF4F, such as that engendered by glucocorticoid exposure, may be correctable by administration of leucine.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Tracy G. Anthony and Sharon Rannels for excellent technical support.
![]() |
FOOTNOTES |
---|
This work was supported by National Institutes of Health Grants DK-15658 (L. S. Jefferson) and T32 GM-08619 (O. J. Shah and J. C. Anthony).
Address for reprint requests and other correspondence: L. S. Jefferson, Dept. of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, PO Box 850, Hershey, PA 17033 (E-mail: jjefferson{at}psu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 11 February 2000; accepted in final form 1 June 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Anthony, JC,
Anthony TG,
Kimball SR,
Vary TC,
and
Jefferson LS.
Orally administered leucine stimulates protein synthesis in skeletal muscle of postabsorptive rats in association with increased eIF4F formation.
J Nutr
130:
139-145,
2000
2.
Anthony, JC,
Anthony TG,
and
Layman DK.
Leucine supplementation enhances skeletal muscle recovery in rats following exercise.
J Nutr
129:
1102-1106,
1999
3.
Dennis, PB,
Fumagalli S,
and
Thomas G.
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation.
Curr Opin Genet Dev
9:
49-54,
1999[ISI][Medline].
4.
Dufner, A,
Andjelkovic M,
Burgering BMT,
Hemmings BA,
and
Thomas G.
Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation.
Mol Cell Biol
19:
4525-4534,
1999
5.
Fabian, JR,
Kimball SR,
and
Jefferson LS.
Reconstitution and purification of eukaryotic initiation factor 2B (eIF2B) expressed in Sf21 insect cells.
Protein Expr Purif
13:
16-22,
1998[ISI][Medline].
6.
Garlick, PJ,
McNurlan MA,
and
Preedy VR.
A rapid and convenient technique for measuring the rate of protein synthesis in tissues by injection of [3H]phenylalanine.
Biochem J
192:
719-723,
1980[ISI][Medline].
7.
Gingras, AC,
Kennedy SG, OLMA,
Sonenberg N,
and
Hay N.
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway.
Genes Dev
12:
502-513,
1998
8.
Grove, JR,
Banerjee P,
Balasubramanyam A,
Coffer PJ,
Price DJ,
Avruch J,
and
Woodgett JR.
Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini.
Mol Cell Biol
11:
5541-5550,
1991[ISI][Medline].
9.
Hara, K,
Yonezawa K,
Weng Q-P,
Kozlowski MT,
Belham C,
and
Avruch J.
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism.
J Biol Chem
273:
14484-14494,
1998
10.
Hong, D-H,
and
Forsberg NE.
Effects of dexamethasone on protein degradation and protease gene expression in rat L8 myotube cultures.
Mol Cell Endocrinol
108:
199-209,
1995[ISI][Medline].
11.
Jefferies, HBJ,
Fumagalli S,
Dennis PB,
Reinhard C,
Pearson RB,
and
Thomas G.
Rapamycin suppresses 5' TOP mRNA translation through inhibition of p70S6k.
EMBO J
16:
3693-3704,
1997
12.
Jefferies, HBJ,
Reinhard C,
Kozma SC,
and
Thomas G.
Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family.
Proc Natl Acad Sci USA
91:
4441-4445,
1994[Abstract].
13.
Jeno, P,
Ballou LM,
Novak-Hofer I,
and
Thomas G.
Identification and characterization of a mitogen-activated S6 kinase.
Proc Natl Acad Sci USA
85:
406-410,
1988[Abstract].
14.
Kimball, SR,
Karinch AM,
Feldhoff RC,
Mellor H,
and
Jefferson LS.
Purification and characterization of eukaryotic initiation factor eIF-2B from liver.
Biochim Biophys Acta
1201:
473-481,
1994[ISI][Medline].
15.
Kimball, SR,
Vary TC,
and
Jefferson LS.
Age-dependent decrease in the amount of eukaryotic imitation factor 2 in various tissues.
Biochem J
286:
263-268,
1992[ISI][Medline].
16.
Kleijn, M,
Scheper GC,
Voorma HO,
and
Thomas AAM
Regulation of translation initiation factors by signal transduction.
Eur J Biochem
253:
531-544,
1998[Abstract].
17.
Li, JB,
and
Jefferson LS.
Influence of amino acid availability on protein turnover in perfused skeletal muscle.
Biochim Biophys Acta
544:
351-359,
1978[ISI][Medline].
18.
Monfar, M,
and
Blenis J.
Inhibition of p70/p85 S6 kinase activities in T cells by dexamethasone.
Mol Endocrinol
10:
1107-1115,
1996[Abstract].
19.
Patel, HR,
Terada N,
and
Gelfand EW.
Rapamycin-sensitive phosphorylation of ribosomal protein S17 by p70 S6 kinase.
Biochem Biophys Res Commun
227:
507-512,
1996[ISI][Medline].
20.
Rannels, DE,
Rannels SR,
Li JB,
Pegg AP,
Morgan HE,
and
Jefferson LS.
Effects of glucocorticoids on peptide chain initiation in heart and skeletal muscle.
In: Advances in Myocardiology, edited by Tajuddin M,
Das PK,
Tariq M,
and Dhalla NS.. Baltimore, MD: University Park, 1980, p. 493-500.
21.
Rannels, SR,
and
Jefferson LS.
Effects of glucocorticoids on muscle protein turnover in perfused rat hemicorpus.
Am J Physiol Endocrinol Metab
238:
E564-E572,
1980
22.
Rannels, SR,
Rannels DE,
Pegg AE,
and
Jefferson LS.
Glucocorticoid effects on peptide-chain initiation in skeletal muscle and heart.
Am J Physiol Endocrinol Metab Gastrointest Physiol
235:
E134-E139,
1978
23.
Savary, I,
Debras E,
Dardevet D,
Sornet C,
Capitan P,
Prugnaud J,
Mirand PP,
and
Grizard J.
Effect of glucocorticoid excess on skeletal muscle and heart protein synthesis in adult and old rats.
Br J Nutr
79:
297-304,
1998[ISI][Medline].
24.
Shah, OJ,
Kimball SR,
and
Jefferson LS.
Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle.
Am J Physiol Endocrinol Metab
278:
E76-E82,
2000
25.
Shah, OJ,
Kimball SR,
and
Jefferson LS.
Among translational effectors, p70S6k is uniquely sensitive to inhibition by glucocorticoids.
Biochem J
347:
389-397,
2000[ISI][Medline].
26.
Shah, OJ,
Kimball SR,
and
Jefferson LS.
Glucocorticoids abate p70S6k and eIF4E function in L6 skeletal myoblasts.
Am J Physiol Endocrinol Metab
279:
E74-E82,
2000
27.
Simmons, PS,
Miles JM,
Gerich JE,
and
Haymond MW.
Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range.
J Clin Invest
73:
412-420,
1984[ISI][Medline].
28.
Thomas, G,
and
Hall MN.
TOR signalling and control of cell growth.
Curr Opin Cell Biol
9:
782-787,
1997[ISI][Medline].
29.
Tischler, ME,
Desantles M,
and
Goldberg AL.
Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle?
J Biol Chem
257:
1613-1621,
1982
30.
Weng, Q-P,
Kozlowski M,
Belham C,
Zhang A,
Comb MJ,
and
Avruch J.
Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies.
J Biol Chem
273:
16621-16629,
1998
31.
Yoshizawa, F,
Kimball SR,
and
Jefferson LS.
Modulation of translation initiation in rat skeletal muscle and liver in response to food intake.
Biochem Biophys Res Commun
240:
825-831,
1997[ISI][Medline].